Thanks, that was an excellent and thorough review. I don't see where they say medication assistance for psychotherapy is not justified. They did say it needs to overcome 'floor effects' of benefit from psychotherapy alone, which is universally true - once a standard of care exists, clinical trials need to show superiority to that, not to placebo. MDMA seems to do that based on the Phase 2 trials and the authors say at the end that if the Phase 3 trials are successful, it is likely to be the first form of MAP to influence clinical practice.